Valuation: NetraMark Holdings Inc.

Market Cap 6.43Cr 4.62Cr 4.01Cr 3.78Cr 3.43Cr 443.18Cr 6.48Cr 45Cr 17Cr 224.83Cr 17Cr 17Cr 714.76Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 6.43Cr 4.62Cr 4.01Cr 3.78Cr 3.43Cr 443.18Cr 6.48Cr 45Cr 17Cr 224.83Cr 17Cr 17Cr 714.76Cr EV / Sales 2026 *
160x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
10/09 NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models CI
01/09 Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors CI
14/08 NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 CI
09/07 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
09/07 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
29/06 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
29/06 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
15/05 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
08/05 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
04/05 NetraMark Holdings Inc. Announces Executive Changes CI
22/04 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
20/04 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
09/04 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.77% - - 4.64Cr
+2.84%+3.00%-1.28%+50.22% 3,68000Cr
+3.43%+1.51%+0.98%+992.10% 40TCr
-2.24%-0.66%-19.71%+16.23% 7.97TCr
+5.39%+10.69%+67.83%+138.64% 7.94TCr
-2.38%-1.15%-7.56%-16.87% 7.62TCr
+3.46%-2.92%-42.23%+175.81% 6.51TCr
+6.79%+8.51%+10.10%-8.58% 4.55TCr
+2.82%+3.66%-10.57%+53.12% 4.03TCr
+1.89%+2.73%+122.11%+259.12% 3.49TCr
Average +2.18%-1.52%+13.30%+184.42% 50.04TCr
Weighted average by Cap. +2.77%-1.11%+0.11%+136.96%

Financials

2026 *2027 *
Net sales 4L 3L 2L 2L 2L 2.76Cr 4L 28.14L 10.84L 1.4Cr 10.82L 10.58L 4.45Cr -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!